TELA Bio (TELA) to Release Earnings on Tuesday

TELA Bio (NASDAQ:TELA) is expected to post its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect TELA Bio to post earnings of ($0.14) per share and revenue of $18.5970 million for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

TELA Bio (NASDAQ:TELA) last released its earnings results on Tuesday, March 24th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.02. The firm had revenue of $20.87 million for the quarter, compared to the consensus estimate of $21.04 million. TELA Bio had a negative net margin of 48.37% and a negative return on equity of 433.58%. On average, analysts expect TELA Bio to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

TELA Bio Price Performance

TELA Bio stock opened at $1.02 on Friday. The company has a market cap of $45.67 million, a price-to-earnings ratio of -1.23 and a beta of 1.30. The firm’s fifty day moving average is $0.75 and its 200 day moving average is $0.97. The company has a quick ratio of 3.59, a current ratio of 4.20 and a debt-to-equity ratio of 8.82. TELA Bio has a 52-week low of $0.50 and a 52-week high of $2.20.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC grew its holdings in shares of TELA Bio by 161.3% in the third quarter. Citadel Advisors LLC now owns 35,281 shares of the company’s stock worth $53,000 after purchasing an additional 21,781 shares during the last quarter. XTX Topco Ltd bought a new position in TELA Bio during the 4th quarter worth about $48,000. Susquehanna International Group LLP grew its holdings in TELA Bio by 551.2% during the 3rd quarter. Susquehanna International Group LLP now owns 85,763 shares of the company’s stock worth $128,000 after acquiring an additional 72,594 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in TELA Bio by 101.4% during the 4th quarter. Renaissance Technologies LLC now owns 128,700 shares of the company’s stock worth $152,000 after acquiring an additional 64,800 shares in the last quarter. 94.35% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Citizens Jmp decreased their price target on shares of TELA Bio from $5.00 to $3.00 and set a “market outperform” rating on the stock in a research note on Friday, March 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TELA Bio in a research note on Tuesday, April 21st. Lake Street Capital decreased their price target on shares of TELA Bio from $3.00 to $2.00 and set a “buy” rating on the stock in a research note on Wednesday, March 25th. Piper Sandler decreased their price target on shares of TELA Bio from $1.25 to $1.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 25th. Finally, Canaccord Genuity Group decreased their price target on shares of TELA Bio from $4.00 to $2.00 and set a “buy” rating on the stock in a research note on Wednesday, March 25th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, TELA Bio has a consensus rating of “Hold” and an average price target of $2.20.

About TELA Bio

TELA Bio, Inc (NASDAQ: TELA) is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.